
STAT+: ASCO showcased the payoff for new cancer medicines: longer lives
As new cancer drugs arrive, regulators and doctors still struggle with when to use drugs based on earlier data and when to wait for survival data. #ASCO23 […]
As new cancer drugs arrive, regulators and doctors still struggle with when to use drugs based on earlier data and when to wait for survival data. #ASCO23 […]
Proving a meaningful survival benefit for patients with a type of blood cancer represents another milestone for CAR-T therapy. #ASCO23 […]
Amid rising demand for drugs like Wegovy and Ozempic that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances… […]
“How do we make sure that a technology like CRISPR — you know, no offense intended — is not just going to make a few people rich, but it’s going… […]
Gilead’s CEO believes the foundation of the company will continue to be its HIV franchise, particularly PrEP. #STATBreakthrough […]
What’s the future of Alzheimer’s disease treatment? How do you pivot from a pandemic? And how successful can Wegovy get? Find out on the new episode of “The Readout LOUD.” […]
A gathering of experts in CAR-T cancer therapy at #STAT breakthrough express optimism about making therapy faster and more accessible, while also raising concerns about falling behind China. […]
“Probably any words I use to describe my emotions at seeing this data will understate it,” said Daniel Skovronsky, Eli Lilly’s head scientist. […]
ImmuneBridge, a San Francisco-based startup, is developing cancer immunotherapies based on so-called natural killer cells. […]
Stanford president Marc Tessier-Lavigne took responsibility for the decision not to correct or retract a paper at the heart of scientific-misconduct allegations. […]
Copyright © 2023 Biotech Networks, LLC